QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
State or Other Jurisdiction of Incorporation or Organization | I.R.S. Employer Identification No. | |||||||
Address of Principal Executive Offices | Zip Code |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Large accelerated filer ☐ | Accelerated filer ☐ | ||||
Smaller reporting company | |||||
Emerging growth company |
Page | ||||||||
June 30, 2023 | December 31, 2022 | ||||||||||
Assets | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Short-term investments | |||||||||||
Prepaid expenses and other assets | |||||||||||
Total Assets | $ | $ | |||||||||
Liabilities and Stockholders’ Equity | |||||||||||
Current Liabilities: | |||||||||||
Accounts payable and accrued expenses (includes related party $ | |||||||||||
Total Liabilities | |||||||||||
Commitments | |||||||||||
Stockholders’ Equity | |||||||||||
Preferred stock - $ | |||||||||||
Common stock - $ | |||||||||||
Additional paid in capital | |||||||||||
Accumulated deficit | ( | ( | |||||||||
Total Stockholders’ Equity | $ | $ | |||||||||
Total Liabilities and Stockholders’ Equity | $ | $ |
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
Operating Expenses: | |||||||||||||||||||||||
General and administrative | $ | $ | $ | $ | |||||||||||||||||||
Research and development | |||||||||||||||||||||||
Total operating expenses | |||||||||||||||||||||||
Loss from operations | ( | ( | ( | ( | |||||||||||||||||||
Other Income | |||||||||||||||||||||||
Interest income | |||||||||||||||||||||||
Total other income | |||||||||||||||||||||||
Loss before provision for income taxes | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Income tax provision | $ | $ | $ | $ | |||||||||||||||||||
Net Loss | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Net loss per share, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Weighted average common shares outstanding, basic and diluted |
Three months ended June 30, 2023 | |||||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | ||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||
Balance - April 1, 2023 | $ | $ | $ | ( | $ | ( | |||||||||||||||||||||||
Stock based compensation expense | — | — | — | ||||||||||||||||||||||||||
Sale of Common Stock, net of issuance costs | — | ||||||||||||||||||||||||||||
Stock issuance upon vesting and exercise of stock options | — | — | |||||||||||||||||||||||||||
Stock issuance upon vesting of restricted stock awards | — | — | — | — | |||||||||||||||||||||||||
Stock issuance upon exercise of warrants | — | — | — | — | — | ||||||||||||||||||||||||
Net loss | — | — | — | ( | ( | ||||||||||||||||||||||||
Balance – June 30, 2023 | $ | $ | $ | ( | $ |
Three months ended June 30, 2022 | |||||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | ||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||
Balance - April 1, 2022 | $ | $ | $ | ( | $ | ||||||||||||||||||||||||
Stock based compensation expense | — | — | — | ||||||||||||||||||||||||||
Stock issuance upon vesting and exercise of stock options | — | — | |||||||||||||||||||||||||||
Stock issuance upon vesting of restricted stock units | — | — | — | ||||||||||||||||||||||||||
Net loss | — | — | — | ( | ( | ||||||||||||||||||||||||
Balance – June 30, 2022 | $ | $ | $ | ( | $ |
Six months ended June 30, 2023 | |||||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | ||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||
Balance - January 1, 2023 | $ | $ | $ | ( | $ | ||||||||||||||||||||||||
Stock based compensation expense | — | — | — | ||||||||||||||||||||||||||
Sale of Common Stock, net of issuance costs | — | ||||||||||||||||||||||||||||
Stock issuance upon vesting and exercise of stock options | — | — | |||||||||||||||||||||||||||
Stock issuance upon vesting of restricted stock awards | — | — | — | — | |||||||||||||||||||||||||
Stock issuance upon exercise of warrants | — | — | |||||||||||||||||||||||||||
Net loss | — | — | — | ( | ( | ||||||||||||||||||||||||
Balance – June 30, 2023 | $ | $ | $ | ( | $ |
Six months ended June 30, 2022 | |||||||||||||||||||||||||||||
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | ||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||
Balance - January 1, 2022 | $ | $ | $ | ( | $ | ||||||||||||||||||||||||
Stock based compensation expense | — | — | — | ||||||||||||||||||||||||||
Sale of Common Stock and warrants | |||||||||||||||||||||||||||||
Stock issuance upon vesting and exercise of stock options | — | — | |||||||||||||||||||||||||||
Stock issuance upon vesting of restricted stock units | — | — | — | ||||||||||||||||||||||||||
Net loss | — | — | — | ( | ( | ||||||||||||||||||||||||
Balance – June 30, 2022 | $ | $ | $ | ( | $ |
Six months ended June 30, | |||||||||||
2023 | 2022 | ||||||||||
Cash Flows From Operating Activities | |||||||||||
Net loss | $ | ( | $ | ( | |||||||
Adjustments to reconcile net loss to net cash used in operating activities | |||||||||||
Stock-based compensation expense | |||||||||||
Changes in operating assets and liabilities: | |||||||||||
Prepaid expenses and other current assets | |||||||||||
Accounts payable and accrued expenses | ( | ||||||||||
Net cash used in operating activities | ( | ( | |||||||||
Cash Flows From Investing Activities | |||||||||||
Purchase of short-term investments | ( | ||||||||||
Net cash used in investing activities | ( | ||||||||||
Cash Flows From Financing Activities | |||||||||||
Proceeds from sale of equity, net of issuance costs | |||||||||||
Proceeds from exercise of stock options | |||||||||||
Proceeds from exercise of warrants | |||||||||||
Net cash provided by financing activities | |||||||||||
Net increase (decrease) in cash | ( | ||||||||||
Cash and Cash Equivalents – Beginning of period | |||||||||||
Cash and Cash Equivalents – Ending of period | $ | $ | |||||||||
Supplemental Disclosures of Cash Flow Information: | |||||||||||
Taxes paid | $ | $ | |||||||||
Supplemental Disclosures of Non-cash Financing Activities: | |||||||||||
Issuance of common stock and warrants to settle accrued expenses | $ | $ |
Three and Six months ended June 30, | ||||||||||||||
2023 | 2022 | |||||||||||||
Stock options (excluding exercisable penny stock options) | ||||||||||||||
Restricted stock awards | ||||||||||||||
Warrants | ||||||||||||||
Total |
Number of shares | Weighted average exercise price | Weighted average remaining life (years) | Aggregate intrinsic value (in thousands) | ||||||||||||||||||||
Outstanding - December 31, 2022 | $ | $ | |||||||||||||||||||||
Issued | — | — | |||||||||||||||||||||
Exercised | ( | — | — | ||||||||||||||||||||
Expired | ( | — | — | ||||||||||||||||||||
Outstanding and Exercisable – June 30, 2023 | $ | $ |
Number of options outstanding | Weighted average exercise price | Average remaining contractual life (in years) | Aggregate intrinsic value (in thousands) | ||||||||||||||||||||
Outstanding – December 31, 2022 | $ | $ | |||||||||||||||||||||
Options granted | — | — | |||||||||||||||||||||
Options exercised | ( | — | — | ||||||||||||||||||||
Options cancelled | ( | — | — | ||||||||||||||||||||
Outstanding – June 30, 2023 | |||||||||||||||||||||||
Exercisable – June 30, 2023 | $ | $ |
Six months ended June 30, | |||||||||||
2023 | 2022 | ||||||||||
Weighted-average Black-Scholes option pricing model assumptions: | |||||||||||
Volatility | |||||||||||
Expected term (in years) | |||||||||||
Risk-free rate | |||||||||||
Expected dividend yield | $ | $ | |||||||||
Weighted average grant date fair value per share | $ | $ |
Six months ended June 30, 2023 | ||||||||||||||
Numbers of Shares | Weighted Average Grant Date Fair value | |||||||||||||
Non-Vested at beginning of period | $ | |||||||||||||
Shares granted | ||||||||||||||
Shares vested | ( | |||||||||||||
Non-vested | $ |
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
General and administrative | |||||||||||||||||||||||
Stock options | |||||||||||||||||||||||
RSU’s | |||||||||||||||||||||||
Total general and administrative | |||||||||||||||||||||||
R&D | |||||||||||||||||||||||
Stock options | |||||||||||||||||||||||
Total | $ | $ | $ | $ |
For three months ended June 30, | For six months ended June 30, | ||||||||||||||||||||||||||||||||||||||||||||||
2023 | 2022 | $ Change | % Change | 2023 | 2022 | $ Change | % Change | ||||||||||||||||||||||||||||||||||||||||
(In thousands, except percentages) | |||||||||||||||||||||||||||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||
General and administrative | $ | 1,828 | $ | 1,793 | $ | 35 | 2 | % | $ | 4,303 | $ | 3,208 | $ | 1,095 | 34 | % | |||||||||||||||||||||||||||||||
Research and development | 1,484 | 1,742 | (258) | (15) | % | 3,165 | 2,475 | 690 | 28 | % | |||||||||||||||||||||||||||||||||||||
Total operating expenses | 3,312 | 3,535 | (223) | (6) | % | 7,468 | 5,683 | 1,785 | 31 | % | |||||||||||||||||||||||||||||||||||||
Loss from operations | (3,312) | (3,535) | 223 | (6) | % | (7,468) | (5,683) | (1,785) | 31 | % | |||||||||||||||||||||||||||||||||||||
Interest income (expense) | 158 | 10 | 148 | 1,480 | % | 178 | 12 | 166 | 1,383 | % | |||||||||||||||||||||||||||||||||||||
Income tax provision | — | — | — | — | % | — | — | — | — | % | |||||||||||||||||||||||||||||||||||||
Net loss | $ | (3,154) | $ | (3,525) | $ | 371 | (11) | % | $ | (7,290) | $ | (5,671) | $ | (1,619) | 29 | % |
June 30, 2023 | December 31, 2022 | |||||||||||||
Cash | $ | 17,401 | $ | 3,594 |
Six months ended June 30, | ||||||||||||||
2023 | 2022 | |||||||||||||
Net cash used in operating activities | $ | (7,137) | $ | (4,268) | ||||||||||
Net cash used in investing activities | (3,939) | — | ||||||||||||
Net cash provided by financing activities | 24,883 | 350 |
Exhibit Number | Description of Exhibit | |||||||
3.1 | ||||||||
3.2 | ||||||||
3.3 | ||||||||
3.4 | ||||||||
31.1 | ||||||||
31.2 | ||||||||
32.1 | ||||||||
32.2 | ||||||||
101.INS | XBRL Instance Document+ | |||||||
101.SCH | XBRL Taxonomy Extension Schema Document+ | |||||||
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document+ | |||||||
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document+ | |||||||
101.LAB | XBRL Taxonomy Extension Label Linkbase Document+ | |||||||
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document+ | |||||||
104 | Cover Page Interactive Data File - The cover page iXBRL tags are embedded within the inline XBRL document+ | |||||||
* | Filed herewith. | |||||||
** | Furnished herewith. | |||||||
+ | Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections. |
HEARTBEAM, Inc. | ||||||||
By: | /s/ Branislav Vajdic | |||||||
Name: | Branislav Vajdic | |||||||
Title: | Chief Executive Officer | |||||||
(Principal Executive Officer) | ||||||||
By: | /s/ Richard Brounstein | |||||||
Name: | Richard Brounstein | |||||||
Title: | Chief Financial Officer | |||||||
Dated: August 10, 2023 | (Principal Financial and Accounting Officer) |
Date: August 10, 2023 | By: /s/ Branislav Vajdic | |||||||
Branislav Vajdic | ||||||||
Chief Executive Officer | ||||||||
(Principal Executive Officer) |
Date: August 10, 2023 | By: /s/ Richard Brounstein | |||||||
Richard Brounstein | ||||||||
Chief Financial Officer | ||||||||
(Principal Financial and Accounting Officer) |
Date: August 10, 2023 | By: /s/ Branislav Vajdic | |||||||
Branislav Vajdic | ||||||||
Chief Executive Officer | ||||||||
(Principal Executive Officer) |
Date: August 10, 2023 | By: /s/ Richard Brounstein | |||||||
Richard Brounstein | ||||||||
Chief Financial Officer | ||||||||
(Principal Financial and Accounting Officer) |
Condensed Balance Sheets (Unaudited) - USD ($) |
Jun. 30, 2023 |
Dec. 31, 2022 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 17,401,000 | $ 3,594,000 |
Short-term investments | 3,939,151 | 0 |
Prepaid expenses and other assets | 292,000 | 445,000 |
Total Assets | 21,632,000 | 4,039,000 |
Current Liabilities: | ||
Accounts payable and accrued expenses (includes related party $1 and $2 respectively) | 570,000 | 1,665,000 |
Total Liabilities | 570,000 | 1,665,000 |
Commitments | ||
Stockholders’ Equity | ||
Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock - $0.0001 par value; 100,000,000 shares authorized; 25,990,516 and 8,009,743 shares issued and outstanding at June 30, 2023 and December 31, 2022 | 3,000 | 1,000 |
Additional paid in capital | 50,535,000 | 24,559,000 |
Accumulated deficit | (29,476,000) | (22,186,000) |
Total Stockholders’ Equity | 21,062,000 | 2,374,000 |
Total Liabilities and Stockholders’ Equity | $ 21,632,000 | $ 4,039,000 |
Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($) |
Jun. 30, 2023 |
Dec. 31, 2022 |
---|---|---|
Current Liabilities: | ||
Related party accounts payable and accrued expenses | $ 570,000 | $ 1,665,000 |
Stockholders’ Equity | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 25,990,516 | 8,009,743 |
Common stock, shares outstanding (in shares) | 25,990,516 | 8,009,743 |
Related Party | ||
Current Liabilities: | ||
Related party accounts payable and accrued expenses | $ 1,100 | $ 2,000 |
Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
|
Operating Expenses: | ||||
General and administrative | $ 1,828 | $ 1,793 | $ 4,303 | $ 3,208 |
Research and development | 1,484 | 1,742 | 3,165 | 2,475 |
Total operating expenses | 3,312 | 3,535 | 7,468 | 5,683 |
Loss from operations | (3,312) | (3,535) | (7,468) | (5,683) |
Other Income | ||||
Interest income | 158 | 10 | 178 | 12 |
Total other income | 158 | 10 | 178 | 12 |
Loss before provision for income taxes | (3,154) | (3,525) | (7,290) | (5,671) |
Income tax provision | 0 | 0 | 0 | 0 |
Net Loss | $ (3,154) | $ (3,525) | $ (7,290) | $ (5,671) |
Net loss per share, basic (in dollars per share) | $ (0.16) | $ (0.43) | $ (0.52) | $ (0.70) |
Net loss per share, diluted (in dollars per share) | $ (0.16) | $ (0.43) | $ (0.52) | $ (0.70) |
Weighted average common shares outstanding, basic (in shares) | 19,690,251 | 8,145,967 | 13,910,365 | 8,092,237 |
Weighted average common shares outstanding, diluted (in shares) | 19,690,251 | 8,145,967 | 13,910,365 | 8,092,237 |
ORGANIZATION AND OPERATIONS |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND OPERATIONS | ORGANIZATION AND OPERATIONS HeartBeam, Inc. (“HeartBeam” or the “Company”) is a cardiac technology company focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (“ECG”) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company’s ability to develop higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented Vector Electrocardiography (“VECG”) technology platform. HeartBeam’s VECG is capable of developing three-dimensional (3D) images of cardiac electrical activity by displaying the spatial locations of ECG waveforms that demonstrated in early studies to deliver equal or superior diagnostic capability than traditional hospital-based ECG systems. The Company has validated this novel technology and is seeking U.S. Food and Drug Administration (“FDA”) clearance of its initial telehealth products during 2023 and 2024. The Company was incorporated in 2015 as a Delaware corporation. The Company’s operations are based in Santa Clara, California and operates as one segment.
|
LIQUIDITY, GOING CONCERN AND OTHER UNCERTAINTIES |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
LIQUIDITY, GOING CONCERN AND OTHER UNCERTAINTIES | LIQUIDITY, GOING CONCERN AND OTHER UNCERTAINTIES The Company is subject to a number of risks similar to those of early stage companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the potential need to obtain additional capital, competition from larger companies, other technology companies and other technologies. The Company has incurred losses each year since inception and has experienced negative cash flows from operations in each year since inception. As of June 30, 2023 the Company has a cash and cash equivalents and short-term investments balance of approximately $21.3 million. Based on its current business plan assumptions and expected cash burn rate, the Company believes that the existing cash and cash equivalents and short-term investments are sufficient to fund operations for the next twelve months following the issuance of these unaudited condensed financial statements. The Company’s continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships and revenue. The Company expects no material commercial revenue in 2023. Management can provide no assurance that such financing or strategic relationships will be available on acceptable terms, or at all, which would likely have a material adverse effect on the Company and its financial statements.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 16, 2023 (“2022 Annual Report”). CASH AND CASH EQUIVALENTS The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation and has cash balances in accounts which exceed the federally insured limits as of June 30, 2023 and December 31, 2022. SHORT-TERM INVESTMENTS Short-term investments consist of debt securities classified as held-to-maturity and have original maturities greater than 90 days but, less than one year as of the balance sheet date. Held-to-maturity investments are recorded at the amortized cost basis until date of maturity and are carried at amortized cost net of allowance for credit losses, which approximates their fair value determined based on Level 2 inputs. As of June 30, 2023, the short-term investments have an amortized cost basis of $3,939,151. USE OF ESTIMATES The preparation of financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates. NET LOSS PER COMMON SHARE Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2023 and 2022 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect. In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of June 30, 2023, 177,355 penny options have been included in the calculation of weighted average basic and diluted earnings per share. The following is a summary of awards outstanding as of June 30, 2023 and 2022, which are not included in the computation of basic and diluted weighted average shares:
|
STOCKHOLDERS’ EQUITY |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCKHOLDERS’ EQUITY | STOCKHOLDERS’ EQUITY COMMON STOCK On May 2, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor, for the purchase and sale in a registered direct offering of 1,000,000 shares of the Company’s common stock at a price of $1.50 per share, generating net proceeds from the offering of approximately $1.1 million after deducting financial advisory and legal fees as well as other estimated offering expenses. On April 20, 2023, the Company entered into a Placement Agency Agreement with Public Ventures, LLC to consummate an offering of 16,666,666 shares of Common Stock at an offering price of $1.50 per share, which closed in accordance with the subscription agreement dated May 2, 2023. The Company received $23.2 million in net proceeds from the offering after deducting placement agent discounts and commission and other estimated offering expenses payable by the Company. In addition, the subscription agreement grants placement agent warrants to purchase up to 1,666,666 shares of common stock at a per share exercise price of $1.875 and are exercisable after a 180-day lock-up period. The warrants will expire five years from the date of issuance. On February 2, 2023, the Company entered into a securities purchase agreement and a note purchase agreement (“SPA”, NPA” or together “Agreements”) with Maverick Capital Partners, LLC (“Maverick” or “Investor”). Pursuant to the terms of the Agreements, as amended, the Company agreed to sell up to $4,000,000 of the Company’s common stock at 75% of the average calculated Volume Weighted Average Price (“VWAP”) per share. On February 28, 2023, the Company issued a $500,000 Convertible Note to the Investor pursuant to the NPA. On March 9, 2023, the Convertible Note was settled upon the execution of the SPA and related issuance of 200,105 shares of common stock pursuant to the SPA draw down notice dated March 9, 2023. These shares of common stock were registered under the Company’s registration statement on Form S-3 dated February 10, 2023 and the related prospectus supplement dated March 9, 2023, whereby, the Company received total proceeds of $500,000. These were the only transactions consummated under the SPA and NPA and the respective agreements expired on May 31 2023. On February 1, 2023, the Company entered into a Sales Agreement with certain investors to issue and sell through the sales agent shares of the Company’s common stock. The issuance and sale of shares of Common Stock to or through the sales agent will be effected pursuant to the Registration Statement dated February 2, 2023. The Company shall pay to the sales agent in cash, upon each sale of placement shares through the sales agent pursuant to the Sales Agreement, an amount equal to 3.00% of the aggregate gross proceeds from each sale of placement shares. In connection to the Sales Agreement, on February 17, 2023 and February 22, 2023, the Company sold 6,184 shares at $3.76 per share for gross proceeds of approximately $23,000. Total stock issuance costs, which consist primarily of legal, accounting and underwriting fees in connection with the above stated transactions was approximately $174,000, which as of June 30 2023, was fully recorded in additional paid in capital. WARRANTS On May 2, 2023 the Company issued 1,666,666 placement agent warrants to purchase shares of Common Stock sold in the offering, with an exercise price of $1.875 per share and are exercisable for five years from the date of issuance, after a 180-day lockup period. During 2019, milestone warrants to purchase common stock were issued to certain executives totaling 407,272 warrants (“Penny Warrants”). These warrants were valued on the date of grant at $0.0003 and vest upon meeting certain milestones. These warrants expired unissued in February 2023. The following is a summary of warrant activity during the six months ended June 30, 2023:
|
STOCK-BASED COMPENSATION |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATIONIn 2015, the Company’s Board of Directors approved the HeartBeam, Inc. 2015 Equity Incentive Plan ("2015 Plan"), to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company’s business. The 2015 Plan provides for the grant of stock options and RSU’s to purchase common stock of which 1,636,362 were authorized by the board of which 1,083,749 are outstanding. The 2015 Plan was terminated upon shareholder approval of the 2022 Equity Incentive Plan (“2022 Equity Plan”) whereby no new awards can be issued under the 2015 Plan. The Company’s shareholders approved the 2022 Equity Plan at the annual meeting of stockholders held on June 15, 2022, pursuant to which 1,900,000 shares of common stock were authorized for issuance. Under the 2022 Equity Plan, the number of shares available for issuance will be increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of 3,800,000 shares, five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2023 400,487 shares, equivalent to five percent (5%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan. The 2022 Equity Plan includes a provision to add-back any cancelled options from the 2015 Plan up to 1,372,816 shares. As of June 30, 2023, there are 160,689 shares from the 2015 Plan that are included in the 222,885 shares available for issuance under the 2022 Equity Plan. The Company received proceeds of $0.1 million from the exercise of stock options during the quarter ended June 30, 2023 and a de minimis amount during the quarter ended June 30, 2022. STOCK OPTIONS The following is a summary of stock option activity during the six months ended June 30, 2023:
The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the six months ended June 30, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:
RESTRICTED STOCK UNITS The following is a summary of RSU’s awards activity:
STOCK BASED COMPENSATION The following is a summary of stock-based compensation expense:
As of June 30, 2023, total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $3.5 million and $0.01 million, respectively, which is expected to be recognized over a weighted-average period of 2.23 years and 0.03 years, respectively.
|
RELATED PARTY TRANSACTIONS |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | RELATED PARTY TRANSACTIONSDuring the course of business, the Company obtains accounting services from CTRLCFO, a firm in which an executive of the Company has significant influence. The Company incurred accounting fees from this firm of approximately $4,000 and $9,000 during the three and six months ended June 30, 2023, respectively and approximately $4,000 and $11,000 during the three and six months ended June 30, 2022, respectively. The Company had balances due to these firms amounting to approximately $1,100 and $2,000 as of June 30, 2023 and December 31, 2022, respectively. |
COMMITMENTS |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS | COMMITMENTS Lease Obligations On May 1, 2019, the Company entered into a month to month lease agreement for their headquarters. The agreement is for an undefined term and can be cancelled at any time, given one month’s notice by either party. The Company’s monthly rent expense associated with this agreement is approximately $1,440. The Company’s month to month headquarters lease is in the name of the Company’s Chief Executive Officer, and the cost is reimbursed monthly. For the three and six months ended June 30, 2023 and 2022, rent expense was approximately $4,000 and $8,000, respectively for each period. Professional Services Agreement In March 2022, the Company entered into a professional services agreement with Triple Ring Technologies, Inc (“TRT”) a co-development company, which was followed by several amendments. The Company currently has one open committed project for device cost reductions totaling $1.7 million. As of June 30, 2023 the Company has a remaining commitment of $0.8 million.
|
SUBSEQUENT EVENTS |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTSAt the July 7, 2023 Annual Shareholders’ Meeting, the proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares from 1,900,000 shares to 5,900,000 shares was approved. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) |
6 Months Ended |
---|---|
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION | BASIS OF PRESENTATIONThe accompanying condensed unaudited financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission (“SEC”) and have been prepared on a basis which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results of operations for the periods presented. The interim operating results are not necessarily indicative of results that may be expected for any subsequent period. The accompanying condensed unaudited financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Form 10-K filed with the SEC on March 16, 2023 (“2022 Annual Report”). |
CASH AND CASH EEQUIVALENTS | CASH AND CASH EQUIVALENTS The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash deposits. The Company maintains its cash in institutions insured by the Federal Deposit Insurance Corporation and has cash balances in accounts which exceed the federally insured limits as of June 30, 2023 and December 31, 2022.
|
SHORT-TERM INVESTMENTS | SHORT-TERM INVESTMENTSShort-term investments consist of debt securities classified as held-to-maturity and have original maturities greater than 90 days but, less than one year as of the balance sheet date. Held-to-maturity investments are recorded at the amortized cost basis until date of maturity and are carried at amortized cost net of allowance for credit losses, which approximates their fair value determined based on Level 2 inputs. As of June 30, 2023, the short-term investments have an amortized cost basis of $3,939,151. |
USE OF ESTIMATES | USE OF ESTIMATES The preparation of financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based on amounts that differ from those estimates.
|
NET LOSS PER COMMON SHARE | NET LOSS PER COMMON SHARE Basic net loss per share excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding. Diluted net loss per share is computed by giving effect to all potential shares of common stock, including stock options and warrants to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three and six months ended June 30, 2023 and 2022 as the inclusion of all potential common shares outstanding would have an anti-dilutive effect. In accordance with ASC 260-10-45-13, exercisable penny options are included in the calculation of weighted average basic and diluted earnings per share. As of June 30, 2023, 177,355 penny options have been included in the calculation of weighted average basic and diluted earnings per share.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following is a summary of awards outstanding as of June 30, 2023 and 2022, which are not included in the computation of basic and diluted weighted average shares:
|
STOCKHOLDERS’ EQUITY (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights | The following is a summary of warrant activity during the six months ended June 30, 2023:
|
STOCK-BASED COMPENSATION (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option, Activity | The following is a summary of stock option activity during the six months ended June 30, 2023:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | For the six months ended June 30, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Nonvested Restricted Stock Units Activity | The following is a summary of RSU’s awards activity:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount | The following is a summary of stock-based compensation expense:
|
ORGANIZATION AND OPERATIONS (Details) |
6 Months Ended |
---|---|
Jun. 30, 2023
segment
| |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of operating segments | 1 |
LIQUIDITY, GOING CONCERN AND OTHER UNCERTAINTIES (Details) $ in Millions |
Jun. 30, 2023
USD ($)
|
---|---|
Commitments and Contingencies Disclosure [Abstract] | |
Cash, cash equivalents, and short term investments | $ 21.3 |
STOCKHOLDERS’ EQUITY - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands |
6 Months Ended | |||
---|---|---|---|---|
Jun. 30, 2023 |
May 02, 2023 |
Dec. 31, 2022 |
Dec. 31, 2019 |
|
Equity [Abstract] | ||||
Warrants outstanding (in shares) | 5,152,397 | 1,666,666 | 3,908,276 | 407,272 |
Grant date fair value per share, warrants (in dollars per share) | $ 0.0003 | |||
Warrants exercised (in shares) | 11,638 | |||
Cashless warrants exercised (in shares) | 5,817 | |||
Number of warrants utilized in cashless exercise (in shares) | 4,347 | |||
Stock issuance upon exercise of warrants (in shares) | 1,471 | |||
Number of warrants exercised for cash (in shares) | 5,821 | |||
Payments for repurchase of warrants | $ 16 |
STOCK-BASED COMPENSATION - Assumptions (Details) - USD ($) |
6 Months Ended | |
---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
|
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility | 110.23% | 107.25% |
Expected term (in years) | 5 years 8 months 15 days | 5 years 8 months 23 days |
Risk-free rate | 3.54% | 1.47% |
Weighted average grant date fair value per share (in dollars per share) | $ 1.73 | $ 1.08 |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Volatility | 111.73% | 110.98% |
Expected term (in years) | 6 years 25 days | 5 years 9 months 18 days |
Risk-free rate | 3.80% | 2.85% |
Weighted average grant date fair value per share (in dollars per share) | $ 3.38 | $ 1.75 |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected dividend yield | $ 0 | $ 0 |
STOCK-BASED COMPENSATION - Restricted Stock Units (Details) |
6 Months Ended |
---|---|
Jun. 30, 2023
$ / shares
shares
| |
Weighted Average Grant Date Fair value | |
Shares granted (in dollars per share) | $ / shares | $ 2.24 |
RSU’s | |
Numbers of Shares | |
Non-vested, beginning balance (in shares) | shares | 253,970 |
Shares granted (in shares) | shares | 5,000 |
Shares vested (in shares) | shares | (12,500) |
Non-vested, ending balance (in shares) | shares | 246,470 |
Weighted Average Grant Date Fair value | |
Non-Vested at beginning of period (in dollars per share) | $ / shares | $ 1.47 |
Shares vested (in dollars per share) | $ / shares | 2.82 |
Non-vested, ending balance (in dollars per share) | $ / shares | $ 1.44 |
RELATED PARTY TRANSACTIONS (Details) - USD ($) |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
|
Related Party Transaction [Line Items] | |||||
Investments from related parties | $ 4,000 | $ 4,000 | $ 9,000 | $ 11,000 | |
Related party accounts payable and accrued expenses | 570,000 | 570,000 | $ 1,665,000 | ||
Related Party | |||||
Related Party Transaction [Line Items] | |||||
Related party accounts payable and accrued expenses | $ 1,100 | $ 1,100 | $ 2,000 |
COMMITMENTS (Details) - USD ($) |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
May 01, 2019 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
|
Long-term Purchase Commitment [Line Items] | |||||
Operating lease, prior notice for cancellation | 1 month | ||||
Monthly rent expense | $ 1,440 | ||||
Rent expense | $ 4,000 | $ 8,000 | $ 4,000 | $ 8,000 | |
Committed project for device cost reductions | 1,700,000 | ||||
Remaining commitment | $ 800,000 | $ 800,000 |
SUBSEQUENT EVENTS (Details) - 2022 Equity Plan - shares |
Jul. 07, 2023 |
Jun. 30, 2023 |
Jun. 15, 2022 |
---|---|---|---|
Subsequent Event [Line Items] | |||
Number of shares authorized for issuance (in shares) | 222,885 | 1,900,000 | |
Subsequent Event | |||
Subsequent Event [Line Items] | |||
Number of shares authorized for issuance (in shares) | 5,900,000 |
FYA%.(XT#>:0>,R*#4U"Y+=\ "[/6VSN5=7
M[LVAH;%<86NFNVK!,*%D7!<\!XH1B6+D\2CVI%4(8O)3%/E86V! L H%U^A$K=0E7KZ
M>/=FBEWW,[JB:Y;G.O"P78#5&8]-?N ^0WM!;_@P2+F>.QO8X+CE<6RER!>X
M 8?JYWUP^^@FON-VG>B+S?#$'_"AI6&,K0QQ5VPV:7G?0%+TA 7X]@],1&LJX/H,38 +N&.?V='42
M&*O&<0;%OO)56SEZI?+71G0A#CL0A5$,B]D(3D_._J<)K)F#H^C@*/*\\2N\
MF:PJ9FS?& U4K""3PC"Q05$PU#!BNN!2-PKA]W"IC;)M\> $(X8-,\]W4ISCQTZSWH&G$N%C@@(TL5 4'XBECC+Y^@[WRKPSN2LQW8;@';
M-7D?%W.1E7/Q#$S(C":)GI83'.$D(.!$3;HL':=U^<@Z\=).=(E;C=V!TT<]
M?VBOME&-P1R(ZA6HGA'U5H@E"9M(O#T2Z*=_%1)C7P>2^ 6);R2Y>24\H*(9
MQM^#^0JA[_8K+,;>#F3I%2R]!I8%Y(X$75V,+MWS)0ZT0BGQ-Z,[>;!&VI4'SG_IAYOX8N1H1#2ED=(F"/S;
MTB5-4VT)^G7I/#CS0"1=\O0?%JOD8C0=H9BN2)&J'WSW
M!ZT=*@%&/)7E7[2K9"?!"$6%5#RKE0%!QO+J/WFL W&@X XIX%H!=Q7\ 06O
M5O!*1RMDI5M?B"*+N> [)+0T6-.+,C:E-GC#
"JR!9"66B7:ZXD2AC9E<+(1*\B4N6.#YOD]_3*\X
M'*1G+3,K[S2+9):A_:$Q^L&X@=Q")9&@Y2=!=^BS0B@GPF-+D0O%#6G( 8B%
MDI$0L68+)3,KO&T +_#^.0$RB'1#L@(T:)I:K%G ;(!#7$96V"+)>1XE/&4\
M?DJT5!OK:BJ6>+00,)YKM@8TT:^$(L40(BLZWNH4SX!B+727TC.!%RFR\X8,
M35-4@
ZA?C=,:.:[:?1&=X[](<>0X:4098Z07)?#*]6U@77<
MV_.K"7JPYS5.[04NU@K.6$HS7(UV0#WNH![_--2O9/V$1X^^W>* F2>R ?E]
M71B]L_7N-/,KK?=V?&]SEASA!A6<[AKP#Q'6=%W=U:_^OOM^LFF_H+1_?$T[
MIN#PH
]_ T_SJ;?P&+A[N9-[M9@L]@+N;A'6$,+! %'HECD;CE!E($+GS$
M(8[8)V'UM/3!Q<^?QC(7_N6CR$'ERW7IB_:&+Q:X)PG?,'"3A"ALXF415QV<
MM@_N6NLE_"-++H&N_ HT1=,[_/%^'*YUP/U^N(\" 5>[X(UH]#I5>L&GO\$W
M33@.<93EA0*6*,@HYA@)M5Z#*!."@14E<9Z6-..P*"JR C>0)CA9ERDK<_7W
MG2 &,XYB]D]7DDHOC&XO\G7HBJ4P0!-)+#0,T2V2W%]^4BWEMRZ%AR3S!R)K
MJ&_4ZAM][.YR0RC_S!&- 4ZVB'&Q^''6I5_)8Q4\^;*[=75'=U13'